 - Patients must have failed prior treatment for their multiple myeloma MM including a proteasome inhibitor and immunomodulatory drug so-called double refractory. Patients who have received prior salvage combination chemotherapy after failure of proteasome inhibitor and immunomodulatory drug are eligible frank relapse at the time of enrollment is not required 